This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Scientific (TMO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $515.25, marking a -1.06% move from the previous day.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) continued strength across its end markets and the the execution of the growth strategy.
Thermo Fisher's (TMO) Unveils Orbitrap Astral Spectrometer
by Zacks Equity Research
Thermo Fisher's (TMO) OrbitrapTM AstralTM mass spectrometer enables accurate and exact quantification in proteomics laboratories.
Thermo Fisher Scientific (TMO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed at $520.14 in the latest trading session, marking a +0.15% move from the prior day.
Thermo Fisher (TMO) Down 4.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Thermo Fisher (TMO) Expands Manufacturing Facility in APAC
by Zacks Equity Research
Thermo Fisher (TMO) latest expansion will enable it to better assist clients in accelerating their research, development and marketing of medications and vaccines in the Asia-Pacific region.
Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays
by Zacks Equity Research
Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.
Buy These Standout Large-Cap Stocks for Long-Term Upside?
by Benjamin Rains
There are many great stocks with proven and resilient businesses that investors should feel comfortable buying now at rather attractive levels and holding for the long haul. The two stocks we dive into today are Thermo Fisher Scientific Inc. (TMO) and Visa Inc. (V).
The Zacks Analyst Blog Highlights Broadcom, Bank of America, Thermo Fisher Scientific, Chubb Limited and Aon
by Zacks Equity Research
Broadcom, Bank of America, Thermo Fisher Scientific, Chubb Limited and Aon are part of the Zacks top Analyst Blog.
Top Stock Reports for Broadcom, Bank of America & Thermo Fisher Scientific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Bank of America (BAC) and Thermo Fisher Scientific (TMO).
Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing
by Zacks Equity Research
Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.
Compared to Estimates, Thermo Fisher (TMO) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aircraft Skew Durable Goods, Boeing Mixed in Q1
by Mark Vickery
There's no bigger aircraft maker on the planet than Boeing (BA), which posted mixed results in its Q1 report this morning.
Trade Deficit Comes in Lesser Than Expected
by Zacks Equity Research
Trade Deficit Comes in Lesser Than Expected.
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
The year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments drove Thermo Fisher's (TMO) Q1 revenues.
Thermo Fisher Scientific (TMO) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.62% and 1.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q1 Earnings on Apr 25: BSX, TMO and More
by Urmimala Biswas
MedTech companies' results are likely to reflect a sequential decline. Let's see how BSX, TMO, EW and ALGN fare this time.
Why Thermo Fisher (TMO) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $571.68, marking a +1.02% move from the previous day.
What's in Store for Thermo Fisher (TMO) in Q1 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) is likely to have generated growth in the first quarter, driven by a favorable business mix and new launches.
Thermo Fisher Scientific (TMO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $588.60, marking a -0.04% move from the previous day.
The Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, Lockheed Martin, Boston Scientific and Canadian Pacific Railway
by Zacks Equity Research
Eli Lilly, Thermo Fisher Scientific, Lockheed Martin, Boston Scientific and Canadian Pacific Railway are part of the Zacks top Analyst Blog.
Top Analyst Reports for Eli Lilly, Thermo Fisher Scientific & Lockheed Martin
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Thermo Fisher Scientific Inc. (TMO) and Lockheed Martin Corporation (LMT).
TMO vs. ISRG: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. ISRG: Which Stock Is the Better Value Option?